Francesca Cottino

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.

Journal: Nature

Published: February 16, 2026

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.

Journal: Cell death & disease

Published: October 07, 2025

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer.

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer.

Journal: Science translational medicine

Published: May 21, 2025

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

Journal: Cancer discovery

Published: April 18, 2024

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 30, 2023

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.

Journal: Science translational medicine

Published: August 16, 2023

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.

Journal: Nature communications

Published: April 26, 2023

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 16, 2022

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 06, 2019

HER2 activating mutations are targets for colorectal cancer treatment.

HER2 activating mutations are targets for colorectal cancer treatment.

Journal: Cancer discovery

Published: August 06, 2015

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Journal: Science translational medicine

Published: January 30, 2015

The genomic landscape of response to EGFR blockade in colorectal cancer.

The genomic landscape of response to EGFR blockade in colorectal cancer.

Journal: Nature

Published: November 17, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026